The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Abstract
Standardized guidelines for the baseline evaluation and response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparability among clinical trials for newly diagnosed patients. The relative rarity of this tumor precludes rapid completion of large-scale phase III trials and, therefore, our reliance on the results of well-designed phase II trials is critical. To formulate this recommendation, an international group of experts representing hematologic oncology, medical oncology, neuro-oncology, neurology, radiation oncology, neurosurgery, and ophthalmology met to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy. The response guidelines were based on the results of neuroimaging, corticosteroid use, ophthalmologic examination, and CSF cytology. A critical issue that requires additional study is the optimal method to assess the neurocognitive impact of therapy and address the quality of life of PCNSL survivors. We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B., & Schultz, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.013 · Cited by 738
Self-citationNelson, D. F., Martz, K. L., Bonner, H., Nelson, J. S., Newall, J., Kerman, H. D., Thomson, J. W., & Murray, K. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90538-s · Cited by 635
Buccheri, G., Ferrigno, D., & Tamburini, M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00664-8 · Cited by 629
Treatment for Primary CNS Lymphoma: The Next Step
Abrey, L. E., Yahalom, J., & DeAngelis, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3144 · Cited by 607
Self-citationBatchelor, T., Carson, K., O’Neill, A., Grossman, S. A., Alavi, J., New, P., Hochberg, F., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 546
Self-citationCombined modality therapy for primary CNS lymphoma.
DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 544
Self-citationCerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results
Glantz, M. J., Cole, B. F., Glantz, L. K., Cobb, J., Mills, P., Lekos, A., Walters, B. C., & Recht, L. D. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980215)82:4<733::aid-cncr17>3.0.co;2-z · Cited by 456
Cited by
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Brain Metastases: The HER2 Paradigm
Lin, N. U., & Winer, E. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2478 · Cited by 417
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0613 · Cited by 409
Self-citationRubenstein, J. L., Fridlyand, J., Abrey, L., Shen, A., Karch, J., Wang, E., Issa, S., Damon, L., Prados, M., McDermott, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7311 · Cited by 327
Self-citation
Metadata
- Authors
- Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., Neuwelt, E. A., O'Neill, B. P., Thiel, E., Shenkier, T., Graus, F., van den Bent, M., Seymour, J. F., Poortmans, P., Armitage, J. O., & Cavalli, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-01
- Volume
- 23
- Issue
- 22
- Pages
- 5034-5043
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149603266
- Cited by
- 914
- References
- 16
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2005.13.524
- The paper
- Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., Neuwelt, E. A., O'Neill, B. P., Thiel, E., Shenkier, T., Graus, F., van den Bent, M., Seymour, J. F., Poortmans, P., Armitage, J. O., & Cavalli, F. (2005). Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.13.524
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
